Scilex Holding Company (SCLX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Scilex Holding Company (NASDAQ: SCLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.85 (-10.19% 1D, market cap $15.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCLX ranks #471 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).
Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 12.2% FCF Margin ($3.7M FCF) & 415.8% Gross Margin
SEC Form 4 / 13F Thermometer: 45% Net Buy • Disciplined Float (-0.40% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While SCLX currently carries a cautious 40/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.02) and Max Pain ($1.94) forces dealer call-delta covering toward $17.65.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Scilex Holding Company (SCLX) dropped -10.19% to $1.85, trading at 2% of its 52-week range ($1.83 – $16.81). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares increased
Its restatement takes every reported bitcoin off the books, including 837 BTC Scilex agreed to buy in June. No definitive deal has been disclosed.
Datavault AI says it has been unable to withdraw its Bitcoin from Biconomy since June and will restate four financial reports tied to a $150 million Scilex deal.
A $150 million Bitcoin deal left Datavault AI unable to reach its coins. Its stock lost half its value. What happened?
Crypto treasury firm Datavault AI (NASDAQ: $DVLT) says it is unable to access a large portion of its Bitcoin (CRYPT...
Datavault AI shares plunge nearly 40% after invalidating financial statements tied to a $150M Bitcoin deal.
* Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9. ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.
DataMEDS AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its
Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their outstanding shares is
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -46.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SCLX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SCLX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Scilex Holding Company (SCLX) ranks #471 by composite RQD confidence (40/100, grade D-) and #850 by equity capitalization ($15.7M). Within this direct 5-issuer industry benchmark cohort, SCLX leads on earnings valuation at N/A trailing P/E, while SCLX leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. SCLX currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SCLX
ACTIVE
Scilex Holding Company | D- | 40/100 | — | 96.0% | -35.0% | -10.19% | $15.7M | Benchmark Subject |
| DYAI Dyadic International Inc. | E | 31/100 | — | 24.9% | -35.0% | +5.32% | $15.2M | /dyai-vs-sclx → |
| ABOS Acumen Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | -90.82% | $15.2M | /abos-vs-sclx → |
| PLUR Pluri Inc. | E | 34/100 | — | 49.0% | -35.0% | +3.33% | $16.7M | /plur-vs-sclx → |
| JSPR Jasper Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -2.22% | $17.3M | /jspr-vs-sclx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scilex Holding Company (SCLX) reported GAAP revenue of $30.3M (-46.5% vs. FY2024 revenue of $56.6M , and -35.3% cumulative change since FY2023) , GAAP net income of -$374.1M, operating cash flow of $3.8M, and free cash flow of $3.7M (-81.0% YoY). On the balance sheet, SCLX closed FY2025 with $365.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $30.3M | -$374.1M | $3.8M | $3.7M | $365.0M | — |
| FY2024 (FY) | 2024-12-31 | $56.6M | -$72.8M | $19.3M | $19.3M | $93.0M | — |
| FY2023 (FY) | 2023-12-31 | $46.7M | -$114.3M | -$20.7M | -$20.7M | — | — |
As of 2026-11-03, Scilex Holding Company (NASDAQ: SCLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.85 (-10.19% 1D, market cap $15.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCLX ranks #471 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, DYAI (Dyadic International Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).
Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SCLX last traded at $1.85 (-10.19% on volume of 49,895 shares), positioning the stock -53.98% below its 50-day simple moving average ($4.02) and -64.83% below its 200-day simple moving average ($5.26). Across its 52-week range of $1.83 to $16.81, SCLX sits at the 0.1% percentile with a 14-day RSI of 20.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.62 to $2.08).
Why SCLX Stock dropped -10.19% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, SCLX carries an RQD Score of 40, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are scored as follows:
Taken together, the pillars indicate that the valuation discount (price of $2.06 against a 52-week range of $1.83–$16.81) reflects a deteriorated fundamental and flow picture rather than a clear mispricing. Upside drivers would need to come from a reversal in operating losses or a shift in institutional and insider positioning, neither of which is evidenced in the source data. The rating framework therefore frames SCLX as a high-risk profile where the downside factors currently outweigh the supportive ones.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $30.3M | $-346.0M | $-374.1M | N/A | $3.7M | $5.0M | N/A |
| FY 2024 (filed 2024-12-31) | $56.6M | $-83.4M | $-72.8M | N/A | $19.3M | $3.3M | N/A |
| FY 2023 (filed 2023-12-31) | $46.7M | $-105.4M | $-114.3M | N/A | $-20.7M | N/A | N/A |
Per the SEC financials, revenue declined from $56.6M in FY 2024 to $30.3M in FY 2025, while net loss widened to $-374.1M. Per the market data, net margin is -60% and ROIC is -35%. Per the Roarable RQD rating, the forensic pillar cites an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity ratio of 0.5, which together describe a balance sheet with limited financial strength. Reported cash of $5.0M against a net loss of $-374.1M highlights liquidity sensitivity in the source data.
Real-time company headlines, analyst actions, and sector developments for Scilex Holding Company (SCLX) • Click "Debate This Headline" to argue it in the Roar Pit below
Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares increased
Its restatement takes every reported bitcoin off the books, including 837 BTC Scilex agreed to buy in June. No definitive deal has been disclosed.
Datavault AI says it has been unable to withdraw its Bitcoin from Biconomy since June and will restate four financial reports tied to a $150 million Scilex deal.
A $150 million Bitcoin deal left Datavault AI unable to reach its coins. Its stock lost half its value. What happened?
Crypto treasury firm Datavault AI (NASDAQ: $DVLT) says it is unable to access a large portion of its Bitcoin (CRYPT...
Datavault AI shares plunge nearly 40% after invalidating financial statements tied to a $150M Bitcoin deal.
* Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9. ("Datavault AI") (NASDAQ:DVLT), Data Health Partners, Inc.
DataMEDS AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its
Welcome to the SCLX (Scilex Holding Company) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SCLX, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Scilex Holding Company expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SCLX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $2.06 (52-wk range $1.83 - $16.81), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).